Currently Chief Scientific Officer at AKL Therapeutics Ltd (http://www.aklrd.com), a company that identifies secondary metabolites of plant origin with proven efficacy and safety, which are then synthesized before undergoing standard pharmaceutical clinical development.

I am an experienced, commercially aware, broad based scientist who can rapidly assimilate knowledge in new therapeutic areas and apply this knowledge to provide strategic input into development of life cycle plans. I have excellent interactive and presentation skills with all functions in a multi-layered pharmaceutical company at all levels of seniority. 

Following a degree in Applied Biology at Brunel University, I worked at Glaxo before undertaking microbiology research at the Royal Free Hospital in London and the University of London School of Pharmacy. I then undertook various roles in Clinical Research at Ayerst/Wyeth, across a range of therapeutic areas including diabetes, CNS, gastroenterology, and inflammation, providing Strategic Scientific Support, Health Technology Assessment, and Clinical Trial design and strategy. I was project lead for all submissions to NICE for the biologic etanercept 

Following promotion to European Clinical Science Director Inflammation in 2006, I was responsible for:

• Strategic scientific input into clinical, commercial and access programmes

• Co-Chair of Optimisation Expert Panel and member of three other Expert Panels

• Project lead for internal training programme

• Membership of various global internal teams (Asset Teams, Publication strategy, investigator initiated protocol approval etc)

Twice I was awarded the President's Achieving Excellence Award

From 2010 I undertook consultancy work for a number of companies involved in thepharmaceutical industry including Pfizer, Napp, UCB, and Norgine. 

I have authored one book chapter, 26 peer reviewed papers, 5 letters to and 45 abstracts